Kanamycin

Introduction Overview

Generic Name

kanamycin

Brand Name

Kantrex

Dosage Form

Injection (Solution)

Drug Class

Aminoglycosides

Pharmacokinetics

Absorption:
Kanamycin is poorly absorbed from the gastrointestinal tract and is therefore administered parenterally, usually via intramuscular or intravenous injection to achieve therapeutic plasma concentrations. Following intramuscular administration, kanamycin is rapidly absorbed, with peak plasma concentrations reached within 30 to 60 minutes. The bioavailability after intramuscular injection is approximately 90%. Absorption can be influenced by local blood flow and tissue perfusion at the injection site. Oral administration is not considered effective due to minimal systemic absorption.

Distribution:
Kanamycin distributes primarily into extracellular fluid, with a volume of distribution approximating 0.2 to 0.3 L/kg in adults. It does not readily penetrate the cerebrospinal fluid unless the meninges are inflamed. Binding to plasma proteins is negligible (<10%), allowing extensive renal filtration. The drug accumulates in the renal cortex and inner ear fluids, which underpins its nephrotoxic and ototoxic potential. Tissue penetration varies, with adequate concentrations achieved in liver, kidney, and lung tissue; however, limited penetration is noted in the central nervous system.

Metabolism:
Kanamycin is not metabolized to any significant extent in humans. It is administered and eliminated in its active form. Lack of metabolism reduces the risk of forming active or toxic metabolites but necessitates renal clearance for elimination.

Elimination:
Excretion of kanamycin occurs primarily by glomerular filtration in the kidneys. Approximately 90% of an administered dose is excreted unchanged in the urine within 24 hours. Renal clearance corresponds closely to the glomerular filtration rate, and renal impairment significantly prolongs the elimination half-life, which is approximately 2 to 3 hours in individuals with normal renal function. Dose adjustment is crucial in patients with renal insufficiency to prevent accumulation and toxicity. Additionally, aminoglycoside serum concentrations are often monitored to tailor dosing and minimize adverse effects. Clearance is reduced in elderly patients and those with dehydration, further increasing toxicity risk.

Dosage Forms

Available Dosage Forms:
Kanamycin is available exclusively as an injection solution for intramuscular or intravenous administration. Specific commercial formulations include injectable vials containing kanamycin sulfate concentrated to deliver doses such as 250 mg/mL or 500 mg/mL of kanamycin base. The solution is isotonic and prepared to allow sterile parenteral use.

Dosages for Adults and Adolescents:
The typical dosage regimen for serious infections ranges from 15 mg/kg/day to 30 mg/kg/day, divided into two to three doses administered every 8 to 12 hours, depending on the severity and sensitivity of the infecting organism. Therapy duration typically spans 7 to 10 days. For severe infections or patients with normal renal function, doses may be administered more frequently with careful therapeutic drug monitoring. Dose adjustment is imperative based on renal function and serum drug levels to minimize toxicity.

Specific Patient Populations:
In pediatric populations, kanamycin administration requires vigilance; although efficacy is established, dosing is weight-based, and premature or newborn infants require cautious use due to immature renal function increasing toxicity risk. In geriatric patients, dosage modifications are necessary due to decreased renal clearance associated with aging. Patients with renal impairment require dose reductions proportional to their degree of renal insufficiency. Additionally, close monitoring is essential for patients with neuromuscular disorders, hearing impairment, and those receiving concomitant nephrotoxic or neurotoxic agents. Kanamycin is contraindicated for oral use due to poor absorption and toxicity concerns.

Mechanism Of Action

Kanamycin is an aminoglycoside antibiotic that exerts its bactericidal activity by binding irreversibly to the 30S ribosomal subunit of susceptible bacteria. This binding disrupts protein synthesis at a molecular level, interfering primarily with the initiation complex and causing aberrant reading of mRNA, leading to the incorporation of incorrect amino acids into nascent polypeptide chains.

This mistranslation results in the production of nonfunctional or toxic peptides, ultimately leading to bacterial cell death. The unique interaction with bacterial ribosomes accounts for its potent efficacy against aerobic gram-negative bacilli and certain gram-positive bacteria.

At the cellular level, kanamycin uptake into bacteria occurs via an oxygen-dependent active transport mechanism, which enhances selective toxicity since anaerobic bacteria exhibit intrinsic resistance due to the lack of uptake. Additionally, kanamycin disrupts bacterial membrane integrity, further contributing to bacterial cell death.

Clinically, kanamycin is often reserved for serious infections due to its significant toxicity profile. Its rapid bactericidal activity combined with a post-antibiotic effect enables dosing schedules that maximize efficacy while attempting to limit adverse effects. Compared to other aminoglycosides such as gentamicin or amikacin, kanamycin shares a similar mechanism but has a narrower spectrum and higher toxicity risk, limiting its contemporary use primarily to resistant or salvage scenarios. Numerous clinical studies have demonstrated effectiveness in tuberculosis and complicated bacterial infections, but safety concerns necessitate monitoring protocols for renal and auditory function during therapy.

Pharmacological Actions

Bactericidal activity against aerobic gram-negative and some gram-positive bacteria by inhibiting protein synthesis.
Selective binding to bacterial 30S ribosomal subunit causing disruption of the translation process.
Induction of production of faulty proteins leading to bactericidal cell damage.
Oxygen-dependent active uptake into bacterial cells, limiting efficacy against anaerobic organisms.
Negligible metabolism, predominantly excreted unchanged via kidneys.
Accumulation within renal cortical tissue contributing to nephrotoxicity.
Concentration-dependent killing characteristic with post-antibiotic effects.
Associated potential for ototoxicity due to inner ear tissue accumulation.
Can cause neuromuscular blockade and respiratory paralysis with high doses or in susceptible individuals.
Minimal plasma protein binding allowing extensive renal filtration and elimination.
Not absorbed orally, thus administered parenterally.
Synergistic when combined with beta-lactam antibiotics in certain bacterial infections.
Resistance may develop through enzymatic modification, altered ribosomal binding sites, or decreased drug uptake.
Exhibits low penetration into cerebrospinal fluid unless meninges are inflamed.

Therapeutic Or Clinical Uses

Treatment of serious bacterial infections caused by susceptible strains, particularly gram-negative bacilli.
Salvage therapy for infections resistant to first-line antibiotics.
Used in combination therapy for tuberculosis caused by Mycobacterium tuberculosis, especially drug-resistant strains.
Management of peritonitis and septicemia with susceptible organisms.
Treatment of bone and joint infections caused by susceptible bacteria.
Use in severe respiratory tract infections when alternative agents are ineffective.
Management of complicated urinary tract infections with resistant pathogens.
Adjunctive treatment in infections requiring bactericidal activity in immunocompromised patients.
Off-label or investigational use in multidrug-resistant bacterial infections.
Used when conventional aminoglycosides are contraindicated or ineffective.
Treatment limited to short courses (typically 7 to 10 days) to reduce toxicity risk.
Reserved for hospital or supervised healthcare settings requiring parenteral administration.
Part of combination regimens for endocarditis due to synergistic activity.
Used for infections associated with biofilm-forming pathogens in specialized clinical scenarios.

Side Or Adverse Effects

Ototoxicity manifesting as tinnitus, hearing loss, or balance disturbances; often irreversible.
Nephrotoxicity characterized by acute tubular necrosis and impaired renal function.
Neurotoxicity including neuromuscular blockade leading to muscle weakness and possible respiratory paralysis.
Allergic reactions such as anaphylaxis, rash, pruritus, and angioedema.
Local injection site pain, redness, or inflammation.
Gastrointestinal disturbances including nausea and vomiting.
Headache, dizziness, and vertigo related to vestibular toxicity.
Electrolyte imbalances secondary to renal impairment.
Rare occurrences of hematological abnormalities like thrombocytopenia or leukopenia.
CNS effects such as confusion, agitation, and seizures in severe toxicity.
Hypersensitivity reactions including urticaria and fever.
Muscle twitching or tremors related to neuromuscular effects.
Fatigue and lethargy during prolonged therapy.
Rare reports of skin reactions including rash and photosensitivity.
Changes in urinary parameters such as decreased output or hematuria indicating renal injury.

Precautions

Monitor renal function regularly due to potential nephrotoxicity, particularly in elderly and renally impaired patients.
Conduct baseline and periodic audiometry testing to detect early ototoxicity.
Avoid use in patients with pre-existing hearing loss or balance disorders.
Use caution and adjust dosing in elderly patients due to decreased renal clearance.
Ensure adequate hydration to reduce nephrotoxic risk.
Avoid concurrent use with other nephrotoxic or ototoxic drugs such as loop diuretics.
Use cautiously in patients with neuromuscular diseases (e.g., myasthenia gravis) due to risk of muscle weakness.
Pregnancy use may result in fetal harm; effective contraception recommended during therapy.
Administer only under medical supervision with capability for monitoring serum levels if possible.
Discontinue immediately if signs of hearing loss, tinnitus, or vestibular symptoms develop.
Avoid use in patients with sulfite allergy due to presence of sodium bisulfite in formulation.
Avoid prolonged therapy to minimize cumulative toxicity.
Adjust dose or discontinue in case of significant renal impairment or evidence of drug accumulation.
Monitor for allergic reactions or anaphylaxis during and after administration.
Use caution in pediatric patients, especially premature or neonates, due to immature organ systems.

Warnings

Risk of permanent ototoxicity, which is often irreversible and may affect hearing and balance.
Potential for nephrotoxicity leading to acute renal failure requiring discontinuation or dose modification.
Neuromuscular blockade and respiratory paralysis have been reported; caution during anesthesia or in patients with neuromuscular diseases.
Serious allergic reactions including anaphylaxis may occur; immediate medical attention necessary if symptoms arise.
Serum drug concentration monitoring recommended to avoid toxic levels and optimize therapeutic effect.
Use with caution in patients with preexisting renal disease, hearing impairment, or electrolyte imbalance.
Avoid concurrent use with other neurotoxic, nephrotoxic, or muscle-relaxing agents to prevent additive toxicity.
Pregnancy category D: Potential teratogenic effects; benefits must outweigh risks.
Withdrawal of therapy may not reverse established ototoxicity; early detection critical.
Not for oral use due to poor absorption and risk of systemic toxicity.
Dosage must be carefully adjusted in elderly patients due to altered pharmacokinetics.
Should be administered only by trained healthcare professionals in controlled settings.
Use is generally limited to short duration to reduce cumulative toxicity risk.
Potential for superinfection with prolonged or repeated use.
Patients should be educated on signs of toxicity and instructed to report symptoms promptly.

Contraindication

Hypersensitivity or allergic reaction to kanamycin or other aminoglycosides.
History of severe ototoxicity to aminoglycoside antibiotics.
Patients with pre-existing auditory or vestibular dysfunction are generally contraindicated.
Severe renal impairment without possibility of dosage adjustment and monitoring.
Use of kanamycin in patients receiving ataluren due to harmful drug interaction.
Concurrent administration with other neuromuscular blocking agents without close monitoring.
Known sulfite allergy, as kanamycin preparations may contain sodium bisulfite preservative.
Pregnancy unless benefits clearly outweigh risks due to potential fetal harm.
Patients with myasthenia gravis or other neuromuscular disorders if not closely monitored.
Use in premature neonates without specialized monitoring due to toxicity risk.
Oral use due to poor absorption and risk of systemic side effects.
Use in patients with history of muscular disorders causing respiratory compromise unless necessary.
Concurrent use with drugs causing additive nephrotoxicity or ototoxicity contraindicated unless essential.
Known hypersensitivity to any component of the injectable formulation.
Use in patients with severe dehydration or electrolyte imbalance unless corrected.

Drug Interactions

Ataluren: Concomitant use contraindicated due to serious drug interaction risk.
Neuromuscular blocking agents such as alcuronium, atracurium, cisatracurium, pancuronium, pipecuronium, rocuronium, succinylcholine, tubocurarine, vecuronium: Increased risk of neuromuscular blockade and respiratory paralysis.
Loop diuretics such as furosemide and bumetanide: Enhanced nephrotoxicity and ototoxicity risk.
Ethacrynic acid: Increased risk of additive renal and ototoxic effects.
Colistimethate sodium: Potentiates nephrotoxic and neurotoxic effects.
Tacrolimus: Increased nephrotoxicity when administered concomitantly.
Ascorbic acid: May affect kidney function and drug clearance.
Cidofovir and foscarnet: Combined nephrotoxic potential.
Emtricitabine and tenofovir alafenamide: Possible additive renal adverse effects, caution advised.
Cholera vaccine, live: Interaction not well defined, caution advised before immunization.
Gallamine and mivacurium: Increased risk of prolonged neuromuscular blockade.
Rapacuronium, hexafluorenium, and metocurine: Enhanced neuromuscular blockade effects.
Aspirin and other NSAIDs: Potential increased renal toxicity.
Lysine: Potential metabolic or vascular effects requiring monitoring.
Co-administration with other nephrotoxic or ototoxic agents markedly increases adverse effect risks.
Monitoring of renal function and auditory capacity is mandatory when kanamycin is used with the above agents.

Preparations Of The Drug

Kanamycin sulfate injection available as sterile solutions for intramuscular or intravenous use.
Concentrations commonly include preparations such as 250 mg/mL or 500 mg/mL vials.
Formulated as isotonic aqueous solutions with sodium bisulfite as a preservative.
Supplied in single-dose or multiple-dose vials depending on manufacturer.
Packaging designed for hospital or clinical use within sterile environments.
Reconstitution instructions included for some formulations requiring dilution prior to administration.
Must be stored protected from light and at controlled room temperature to maintain stability.
Labeling includes precise dosing guides, contraindications, and warnings.
No oral or topical formulations available commercially due to poor absorption and risk.
Is supplied under the brand name Kantrex in the United States.
Often packaged with safety information and materials for healthcare professionals.
Prepared in compliance with sterile pharmaceutical manufacturing standards.
Instructions for disposal of unused medications to prevent misuse.
May require refrigeration after opening depending on manufacturer specifications.
Available only by prescription and administered under professional supervision.